Health and Human Services Secretary Robert F. Kennedy Jr. announced the emergency use authorization (EUA) for COVID-19 vaccines has been rescinded, marking a significant shift in federal policy. The move comes after RFK Jr. outlined four key objectives: ensuring vaccine availability for vulnerable populations, demanding placebo-controlled trials from pharmaceutical companies, and prioritizing scientific rigor in public health decisions.
In a statement, RFK Jr. stated that the FDA’s recent actions fulfilled these goals, noting that emergency use authorizations for vaccines—previously used to justify broad mandates during the Biden administration—are no longer in effect. Instead, the agency has granted marketing authorization for specific groups at higher risk, including children aged 6 months and older for Moderna, 5 years and older for Pfizer, and 12 years and older for Novavax. Vaccines will now be available to patients who choose them after consulting with their physicians.
RFK Jr. emphasized that the decision reflects public demand for “science, safety, and common sense,” though critics argue the policy change may limit access for healthy children. The Biden administration ended the COVID-19 public health emergency in May 2023, a move that coincided with the FDA’s transition from EUA to full approval standards. Under EUAs, products are authorized if their benefits outweigh risks, whereas full approval requires proven safety and efficacy.
Last month, the FDA granted full approval for Moderna’s vaccine for children aged 6 months to 11 years, a first for this age group not under an EUA. However, some social media users have criticized RFK Jr.’s announcement, citing concerns over potential harms from the vaccines. Meanwhile, reports suggest the Trump administration may soon ban the jab, though no official action has been confirmed.
Dr. Susan Kressly of the American Academy of Pediatrics called the decision “deeply troubling,” warning that barriers to vaccination could endanger children during respiratory virus season. While doctors can still prescribe vaccines off-label, this approach adds complexity for patients relying on pharmacies. Additionally, the CDC’s vaccine advisory committee—recently reshuffled by RFK Jr.—will determine eligibility, raising questions about future coverage policies.